In the NCT04771273 trial, survodutide—another dual GLP-1/glucagon receptor agonist—was evaluated in patients with biopsy-proven MASH and fibrosis stages F1–F3 [78]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.